Trial 7H-19-1

PhII-191: Phase II Study of XL184 (Cabozantinib) in Combination with Nivolumab and Ipilimumab (CaboNivoIpi) in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy

Type: Treatment
Phase: Phase II
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Other
Randomized: Not Asked
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jorge Nieva, M.D.
Other Trial Staff:  Lusine Raddatz, D.M., Grace Facio, Coordinator, Marissa Aldana, D.M., Mary Ordaz, D.M., Margarita Carranza, D.M., Kristy Sartor Massopust, Coordinator, Eduardo Mejia, D.M., America Casillas-Lopez, Coordinator, Niranjan Bhatt, D.M., Ramy Farag, Coordinator, Brigitte Torres, Coordinator, Sophie Miehl, Coordinator, Sreebharathy Venkatesh, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.